|Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
||CME Credits: 1
|Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC).
|Faculty: Jarushka Naidoo and Beatriz Wills
|Addressing Unmet Needs in Mesothelioma: Evaluating the Role of Angiokinase Inhibitors
||CME Credits: 0.5
|Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Most cases of MPM are associated with workplace exposure to high levels of asbestos, with the onset of cancer typically occurring 20 to 50 years after asbestos exposure.
|Faculty: Patrick Forde, MBBCh